β2-微球蛋白水平与多发性骨髓瘤的相关性研究  

Studies of correlationship between β2-microglobulin levels and multiple myeloma

作　　者：蔡成才[1] 陈建军[1] 黄国权[1] 帅虎[1] 李海珠[1] 

机构地区：[1]肇庆市第一人民医院血液科,广东省肇庆526021

出　　处：《中国基层医药》2007年第4期605-606,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的通过检测多发性骨髓瘤（MM）患者血清β2微球蛋白含量的变化,探讨β2微球蛋白与多发性骨髓瘤的相关性及临床意义。方法采用放射免疫分析法测定并比较55例多发性骨髓瘤患者与55例健康老年对照组β2微球蛋白含量,并参照患者相应时期骨髓瘤细胞百分数进行分析。结果本组55例多发性骨髓瘤患者初发期血β2微球蛋白含量显著高于对照组（P＜0．01）,复发期再度增高,并发肾病肾功能不全期血清β2微球蛋白含量增高更明显,显著高于临床缓解期（P＜0．05）。骨髓瘤患者血清β2微球蛋白水平与瘤细胞百分数及骨髓瘤的严重程度均呈正相关。结论血β2微球蛋白定量检测对多发性骨髓瘤的初发诊断、复发监测、病情严重程度评估均是一项有价值的敏感指标。Objective To investigate the clinical significance of correlationship between serum β2-microglobulin level and multiple myeloma（MM） by detecting the change of β2-MG levels in MM patients. Method The serum β2-MG was determined by radioimmunoassay（RIA） in 55 patients with MM and 55 normal olderly,and the percentage of cancer cell in marrow in relevant stage by reference was analysed. Results The level of β2-MG was significantly higher in the patients with MM who were diagnosed than those of control（P 〈 0.01） and β2-MG was significantly higher in remission stage than in relapse and complication of kidney disease stage（P 〈 0.05）. The percentage of cancer cell was positively correlated with serum β2-MG. Conclusion The serum level of β2-MG in MM patients is a sensitive index to diagnose disease,inspect relapse and evaluate severity.

关 键 词：多发性骨髓瘤 Β2-微球蛋白 

分 类 号：R733[医药卫生—肿瘤]